• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    INVO Fertility Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events

    6/25/26 4:52:22 PM ET
    $IVF
    Medical/Dental Instruments
    Health Care
    Get the next $IVF alert in real time by email
    false 0001417926 0001417926 2026-06-23 2026-06-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): June 23, 2026

     

    INVO FERTILITY, INC.

    (Exact name of registrant as specified in its charter)

     

    Nevada   001-39701   20-4036208
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    5582 Broadcast Court

    Sarasota, Florida 34240

    (Address of principal executive offices)

    (Zip Code)

     

    Registrant’s telephone number, including area code: (978) 878-9505

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class   Trading Symbol   Name of Each Exchange on Which Registered
    Common Stock, $0.0001 par value   IVF   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (CFR §240.12b-2 of this chapter). Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    INVO Centers, LLC, a Delaware limited liability company (“INVO Centers” or “Purchaser”), a wholly owned subsidiary of INVO Fertility Inc., a Nevada corporation (the “Company”), is a party to that certain limited liability company agreement of HRCFG INVO LLC (“HRCFG INVO”) with HRCFG, LLC (“HRCFG”) to establish a joint venture partnership for a fertility clinic in Birmingham, Alabama (the “Alabama JV”). As a joint venture partner, HRCFG operated and managed the clinic under the name of Innovative Fertility Specialists.

     

    On June 23, 2026, the Company consummated the acquisition (the “Acquisition”) of one-hundred percent (100%) of the membership interests of HRCFG pursuant to that certain Membership Interest Transfer Agreement (the “MITA”) by and among Purchaser, Karen Hammond (“Hammond”), Lisa Ray (“Ray”) and Nicholas Cataldo (“Cataldo” and collectively with Hammond and Ray, “Sellers”). Pursuant to the MITA, Sellers transferred all rights, title and interest in their respective membership interests (the “Membership Interests”) of HRCFG to Purchaser for a combined purchase price of $175,001, of which $1.00 was paid in cash on the closing date and $175,000 as additional consideration, $48,000 of which shall be payable to Sellers pro rata in equal monthly installments over a nine (9) month period starting in October 2026 and $127,000 of which shall be paid from HRCFG’s free cash flow.

     

    Pursuant to the MITA, each Seller transferred, granted, conveyed, assigned and relinquished exclusively to HRCFG all of such Seller’s right, title, and interest in and to any assets, rights, or property of any kind that are primarily used in or necessary for the operation and management of the Alabama JV, including, without limitation, any intellectual property rights (collectively, the “Business Properties”). Under the MITA, for a period of approximately four (4) months (the “Transition Period”), Sellers will provide transition services to Purchaser, and for a period of twelve (12) months following the Transition Period (the “Support Period”), Sellers shall make themselves available to support HRCFG.

     

    The Alabama JV is one of the Company’s four existing clinics. As a result of the Acquisition, the Company will now include the accounts of the Alabama JV in its consolidated financial statements on a prospective basis.

     

    Item 8.01 Other Events.

     

    As previously disclosed, the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notified the Company on April 23, 2026 and May 27, 2026 that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Timely Filing Rule”) as a result of its failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “10-K Filing”) and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 (the “10-Q Filing”), respectively.

     

    On June 2, 2026, the Company filed the 10-K Filing with the SEC. On June 9, 2026, the Staff notified the Company that the Company was no longer noncompliant on its 10-K filing, but, as the 10-Q Filing had not been completed, the Company was still noncompliant with the Timely Filing Rule.

     

    On June 23, 2026, the Staff notified the Company that, based on the Company’s 10-Q Filing with the SEC on June 22, 2026, the Company complies with the Timely Filing Rule and the matter is now closed.

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: June 25, 2026

     

      INVO FERTILITY, INC.
         
      By: /s/ Steven Shum
        Steven Shum
        Chief Executive Officer

     

     

     

    Get the next $IVF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IVF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IVF
    SEC Filings

    View All

    INVO Fertility Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events

    8-K - INVO Fertility, Inc. (0001417926) (Filer)

    6/25/26 4:52:22 PM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    SEC Form DEF 14A filed by INVO Fertility Inc.

    DEF 14A - INVO Fertility, Inc. (0001417926) (Filer)

    6/23/26 4:05:35 PM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    INVO Fertility Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - INVO Fertility, Inc. (0001417926) (Filer)

    6/22/26 9:05:10 AM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    $IVF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Krigsvold Terah Renee claimed ownership of 1 shares (SEC Form 3)

    3 - INVO Fertility, Inc. (0001417926) (Issuer)

    1/13/26 8:03:23 PM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    Director Szot Matthew K sold $6 worth of shares (4 units at $1.52) and disposed of 3 shares, closing all direct ownership in the company (SEC Form 4)

    4 - INVO Fertility, Inc. (0001417926) (Issuer)

    12/5/25 9:40:32 PM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Executive Officer Shum Steve

    4 - INVO Fertility, Inc. (0001417926) (Issuer)

    10/3/25 4:05:15 PM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    $IVF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    INVO Fertility Reports First Quarter 2026 Results Reflecting Strong Revenue Growth, Expanded Fertility Clinic Platform, and Improved Capital Structure

    23% revenue growth, elimination of all Series C-2 Preferred Stock and warrant liabilities, and a strengthened balance sheet Growth reflects both organic clinic initiatives and acquisition contribution from Family Beginnings, reinforcing INVO's two primary growth avenues SARASOTA, Fla., June 22, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO Fertility" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced financial results for the first quarter ended March 31, 2026. Q1 2026 Financial Highlights (all metrics compared to Q1

    6/22/26 9:00:00 AM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    INVO Fertility Receives Nasdaq Notification Regarding Late Filing of Quarterly Report on Form 10-Q

    SARASOTA, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO" or the "Company"), a healthcare services fertility company, today announced that on May 27, 2026, it received a delinquency notice (the "Notice") from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). The Notice relates to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the "10-K"), and its Quarterly Report on Form

    6/2/26 4:50:00 PM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    INVO Fertility Announces Fiscal Year 2025 Financial Results

    SARASOTA, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO Fertility" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced fiscal year 2025 financial results. FY2025 Financial Highlights (all metrics compared to FY2024 unless otherwise noted) Revenue was $6,841,250, an increase of 5% compared to $6,532,000.Consolidated clinic revenue increased 4% to $6,721,057, compared to $6,450,431.Revenue from all clinics was $8,021,929, including both consolidated and equity method clinics, an increase of 4% compared to $7,731,177.Net loss

    6/2/26 8:30:00 AM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    $IVF
    Leadership Updates

    Live Leadership Updates

    View All

    INVO Fertility's Wisconsin Clinic Joins Progyny Network

    MIDDLETON, Wis. and SARASOTA, Fla., March 03, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO Fertility" or the "Company"), a healthcare services fertility company focused on expanding access to advanced reproductive treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced that its Wisconsin Fertility Institute (WFI) clinic has joined the Progyny network. Progyny provides fertility and family-building benefits to an estimated 7.2 million covered lives through over 600 employers and plan sponsors nationwide. WFI's participation in the Progyny network significantly expands the clinic's acce

    3/3/26 8:45:00 AM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    INVO Fertility Announces Intent to Acquire Indiana-Based Fertility Clinic "Family Beginnings"

    SARASOTA, Fla. and INDIANAPOLIS, Nov. 28, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced its intent to acquire Family Beginnings, P.C., a respected fertility clinic serving patients across Indiana and the broader Midwest. The planned acquisition marks INVO's second acquisition after its purchase of Wisconsin Fertility Institute in 2023 and reflects the Company's multi-pronged strategic initiative to build a nationwide network of fertility centers capable of reaching underserved markets an

    11/28/25 1:05:00 PM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    $IVF
    Financials

    Live finance-specific insights

    View All

    INVO Fertility Reports First Quarter 2026 Results Reflecting Strong Revenue Growth, Expanded Fertility Clinic Platform, and Improved Capital Structure

    23% revenue growth, elimination of all Series C-2 Preferred Stock and warrant liabilities, and a strengthened balance sheet Growth reflects both organic clinic initiatives and acquisition contribution from Family Beginnings, reinforcing INVO's two primary growth avenues SARASOTA, Fla., June 22, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO Fertility" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced financial results for the first quarter ended March 31, 2026. Q1 2026 Financial Highlights (all metrics compared to Q1

    6/22/26 9:00:00 AM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    INVO Fertility Announces Fiscal Year 2025 Financial Results

    SARASOTA, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO Fertility" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced fiscal year 2025 financial results. FY2025 Financial Highlights (all metrics compared to FY2024 unless otherwise noted) Revenue was $6,841,250, an increase of 5% compared to $6,532,000.Consolidated clinic revenue increased 4% to $6,721,057, compared to $6,450,431.Revenue from all clinics was $8,021,929, including both consolidated and equity method clinics, an increase of 4% compared to $7,731,177.Net loss

    6/2/26 8:30:00 AM ET
    $IVF
    Medical/Dental Instruments
    Health Care

    INVO Fertility Announces 2024 Financial Results with 116% Annual Revenue Growth and Further Improvements in Adjusted EBITDA

    SARASOTA, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO Fertility" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics, today announced fourth quarter and full year 2024 financial results. Q4 2024 Financial Highlights (all metrics compared to Q4 2023 unless otherwise noted) Revenue was $1,685,966, an increase of 22% compared to $1,381,754.Consolidated clinic revenue from the Company's INVO Center in Atlanta, Georgia, and fertility clinic in Madison, Wisconsin increased 24% to $1,687,300, compared to $1,362,938.Revenue from

    4/30/25 9:00:49 AM ET
    $IVF
    Medical/Dental Instruments
    Health Care